<< Back
Aug 6, 2018

Biocept Announces Agreement with Managed Care Plan to Study the Benefits of Implementing Liquid Biopsy to Improve Patient Outcomes and Lower Healthcare Costs

Biocept's Target Selector™ to be used in profiling and monitoring patients diagnosed with non-small cell lung cancer throughout an integrated healthcare delivery system

SAN DIEGO, Aug. 6, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered into an agreement with a large integrated healthcare delivery network to evaluate the clinical utility and cost effectiveness of using Biocept's Target Selector™ testing in patients diagnosed with non-small cell lung cancer (NSCLC). As part of the agreement, the Company's liquid biopsy testing will be used to profile patients who have been diagnosed with NSCLC and/or have progressed on EGFR targeted therapy. Key objectives of the collaboration are to evaluate improvements in the molecular profiling rate of advanced NSCLC patients and the reduction of the overall cost of patient care.

Biocept Logo (PRNewsFoto/Biocept, Inc.)

"We are pleased to enter into this important collaboration, and believe that this initiative will help demonstrate the critical role that our Target Selector™ platform can fulfill in order to ensure that patients are given the option of a targeted therapy," said Biocept's President and Chief Executive Officer Michael Nall. "We remain committed to expanding our relationships with both managed care organizations as well as integrated healthcare delivery networks. Agreements such as this are helping us build upon the body of evidence supporting our proprietary liquid biopsy platform and its ability to help physicians rapidly obtain the actionable molecular information they need to improve patient outcomes."

About Biocept
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement
This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend" or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements as to our ability to improve the outcomes of cancer patients, the utility and cost effectiveness of our tests, our ability to further validate our liquid biopsy technology, and our ability to expand our relationships with managed care organizations and integrated healthcare delivery networks, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this news release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC at www.sec.gov                                                                                          


Cision View original content with multimedia:http://www.prnewswire.com/news-releases/biocept-announces-agreement-with-managed-care-plan-to-study-the-benefits-of-implementing-liquid-biopsy-to-improve-patient-outcomes-and-lower-healthcare-costs-300692222.html

SOURCE Biocept, Inc.

Investor Contact: LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100, Media Contact: Trevelino/Keller, Colleen Murphy, cmurphy@trevelinokeller.com, 404-214-0722, Ext. 109